AI - powered
Search documents
Johns Hopkins Medicine Treats First Commercial TULSA-PRO® Case
Globenewswire· 2026-01-06 12:45
Core Insights - Profound Medical Corp. has achieved a significant milestone with the launch of its TULSA-PRO system at The Johns Hopkins Hospital, marking the beginning of non-clinical-trial treatments for prostate cancer using this advanced technology [1][3] Company Overview - Profound Medical is a commercial-stage medical device company focused on developing and marketing AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue [4] Technology and Procedure - The TULSA Procedure™ utilizes robotically controlled directional ultrasound to treat prostate cancer and benign prostatic hyperplasia (BPH) by heating prostate tissue to 'kill temperature' (55-57°C) while preserving surrounding nerves [2][5] - Real-time MRI thermography allows for continuous visualization and temperature adjustments during the procedure, resulting in no procedural blood loss, no overnight hospital stay, and a quicker recovery for patients [2][5] Clinical Development and Approval - Johns Hopkins University played a crucial role in the clinical development of TULSA-PRO, participating in pivotal clinical trials that led to FDA clearance and further studies to validate its efficacy [3] - TULSA-PRO is CE marked, Health Canada approved, and has received 510(k) clearance from the U.S. FDA, indicating its regulatory compliance and readiness for commercialization [5] Market Potential - The TULSA Procedure has the potential to become a mainstream treatment for a wide range of prostate conditions, including low-, intermediate-, and high-risk prostate cancer, as well as BPH and salvage therapy for radio-recurrent localized prostate cancer [5]
Falcon for IT Risk-based Patching Accelerates Cybersecurity and IT Consolidation on CrowdStrike
Businesswire· 2025-09-17 16:39
AUSTIN, Texas--(BUSINESS WIRE)--Fal.Con 2025, Las Vegas -- CrowdStrike (NASDAQ: CRWD) today announced Risk-based Patching with Falcon® for IT, accelerating cybersecurity and IT consolidation on the Falcon® platform. With the combination of AI-powered Risk-based Patching and Falcon® Exposure Management, customers can identify, prioritize, and fix the vulnerabilities that matter most through a single console and workflow – accelerating safe, large-scale patching and expanding CrowdStrike's platfo. ...